Carstim 100 mg Combipack Injection 1's is a chemotherapeutic medicine used in the treatment of brain tumors. A tumor is defined as the formation of solid mass tissue due to the abnormal growth of cells. A brain tumor is a serious condition where the cells (cancerous or non-cancerous) grow abnormally in the brain. Carstim 100 mg Combipack Injection 1's is also used in the treatment of multiple myeloma in combination with prednisone, Hodgkin’s Disease, and non-Hodgkin’s Disease in combination with other approved drugs.

Carstim 100 mg Combipack Injection 1's contains Carmustine, which belongs to the alkylating agents class. It works by inhibiting the DNA and RNA transcription that is essential for protein synthesis. This causes shrinkage of tumor cells and thereby prevents the growth and further spread of cancerous or non-cancerous cells.

Carstim 100 mg Combipack Injection 1's may cause certain side effects, such as nausea, vomiting, headache, pale skin, dizziness, stomach upset, tiredness, loss of balance, and pain at the site of injection. These side effects do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor. Carstim 100 mg Combipack Injection 1's is a parenteral preparation. A trained healthcare professional will administer it. Hence, do not self-administer.

Carstim 100 mg Combipack Injection 1's should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, or respiratory conditions. Carstim 100 mg Combipack Injection 1's may cause pulmonary toxicity, bone marrow suppression, gastrointestinal toxicity, nephrotoxicity and hepatotoxicity in some patients. Hence, careful monitoring should be done during the entire treatment. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued in nursing mothers during the treatment.

Carstim 100 mg Combipack Injection 1's contains Carmustine, which belongs to the alkylating agents class. It works by inhibiting the DNA and RNA transcription that is essential for protein synthesis. This causes shrinkage of tumor cells and thereby prevents the growth and further spread of cancerous or non-cancerous cells.

Carstim 100 mg Combipack Injection 1's should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, or respiratory conditions. Carstim 100 mg Combipack Injection 1's may cause pulmonary toxicity, bone marrow suppression, gastrointestinal toxicity, nephrotoxicity and hepatotoxicity in some patients. Hence careful monitoring should be done during the entire treatment. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued in nursing mothers during the treatment. It is unknown whether Carstim 100 mg Combipack Injection 1's can be administered in children or not. If administered, close monitoring of the child is needed. Avoid alcohol consumption and smoking as it can lead to serious adverse effects.

• Carstim 100 mg Combipack Injection 1's should be administered only by a trained and experienced oncologist.
• A blood test should be performed such as LFT, RFT, and PFT, to check for liver/kidney function, and pulmonary function.
• Weekly blood tests should be done for at least six weeks after the dose is administered to check for CBC (Complete blood count).
• Carstim 100 mg Combipack Injection 1's should be administered carefully without touching the skin as it can cause serious hyperpigmentation. Hence where gloves during administration.